Cost-effectiveness models for Alzheimer's disease and related
dementias: IPECAD modeling workshop cross-comparison challenge

J 2023

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

HANDELS, Ron L. H.; Colin GREEN; Anders GUSTAVSSON; William L. HERRING; Bengt WINBLAD et al.

Základní údaje

Originální název

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Autoři

Vydání

ALZHEIMERS & DEMENTIA, NEW YORK, ELSEVIER SCIENCE INC, 2023, 1552-5260

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.100

Označené pro přenos do RIV

DOI

https://doi.org/10.1002/alz.12811

UT WoS

000871775600001

Klíčová slova anglicky

Alzheimer's disease; cross-comparison; decision-analytic modeling; dementia; economic evaluation; model validation

Změněno: 30. 1. 2025 09:09, Mgr. Alžběta Karolyiová

Anotace

V originále

Introduction The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge. Methods Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop. Results A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia). Discussion The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.

Citovat

HANDELS, Ron L. H.; Colin GREEN; Anders GUSTAVSSON; William L. HERRING; Bengt WINBLAD; Anders WIMO; Anders SKOLDUNGER; Andreas KARLSSON; Robert ANDERSON; Mark BELGER; Chiara BRUCK; Robert ESPINOSA; Jakub HLÁVKA; Eric JUTKOWITZ; Pei-Jung LIN; Mauricio Lopez MENDEZ; Javier MAR; Peter SHEWMAKER; Eldon SPACKMAN; Ali TAFAZZOLI; Bryan TYSINGER a Linus JONSSON. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. ALZHEIMERS & DEMENTIA. NEW YORK: ELSEVIER SCIENCE INC, 2023, roč. 19, č. 5, s. 1800-1820. ISSN 1552-5260. Dostupné z: https://doi.org/10.1002/alz.12811.

@article{2472545,
   author = {Handels, Ron L. H. and Green, Colin and Gustavsson, Anders and Herring, William L. and Winblad, Bengt and Wimo, Anders and Skoldunger, Anders and Karlsson, Andreas and Anderson, Robert and Belger, Mark and Bruck, Chiara and Espinosa, Robert and Hlávka, Jakub and Jutkowitz, Eric and Lin, PeiandJung and Mendez, Mauricio Lopez and Mar, Javier and Shewmaker, Peter and Spackman, Eldon and Tafazzoli, Ali and Tysinger, Bryan and Jonsson, Linus},
   article_location = {NEW YORK},
   article_number = {5},
   doi = {https://doi.org/10.1002/alz.12811},
   keywords = {Alzheimer's disease; cross-comparison; decision-analytic modeling; dementia; economic evaluation; model validation},
   issn = {1552-5260},
   journal = {ALZHEIMERS & DEMENTIA},
   title = {Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge},
   url = {https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12811},
   volume = {19},
   year = {2023}
}

TY  - JOUR
ID  - 2472545
AU  - Handels, Ron L. H. - Green, Colin - Gustavsson, Anders - Herring, William L. - Winblad, Bengt - Wimo, Anders - Skoldunger, Anders - Karlsson, Andreas - Anderson, Robert - Belger, Mark - Bruck, Chiara - Espinosa, Robert - Hlávka, Jakub - Jutkowitz, Eric - Lin, Pei-Jung - Mendez, Mauricio Lopez - Mar, Javier - Shewmaker, Peter - Spackman, Eldon - Tafazzoli, Ali - Tysinger, Bryan - Jonsson, Linus
PY  - 2023
TI  - Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge
JF  - ALZHEIMERS & DEMENTIA
VL  - 19
IS  - 5
SP  - 1800-1820
EP  - 1800-1820
PB  - ELSEVIER SCIENCE INC
SN  - 15525260
KW  - Alzheimer's disease
KW  - cross-comparison
KW  - decision-analytic modeling
KW  - dementia
KW  - economic evaluation
KW  - model validation
UR  - https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12811
N2  - Introduction The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge. Methods Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop. Results A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia). Discussion The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.
ER  -

HANDELS, Ron L. H.; Colin GREEN; Anders GUSTAVSSON; William L. HERRING; Bengt WINBLAD; Anders WIMO; Anders SKOLDUNGER; Andreas KARLSSON; Robert ANDERSON; Mark BELGER; Chiara BRUCK; Robert ESPINOSA; Jakub HLÁVKA; Eric JUTKOWITZ; Pei-Jung LIN; Mauricio Lopez MENDEZ; Javier MAR; Peter SHEWMAKER; Eldon SPACKMAN; Ali TAFAZZOLI; Bryan TYSINGER a Linus JONSSON. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. \textit{ALZHEIMERS \&{}amp; DEMENTIA}. NEW YORK: ELSEVIER SCIENCE INC, 2023, roč.~19, č.~5, s.~1800-1820. ISSN~1552-5260. Dostupné z: https://doi.org/10.1002/alz.12811.

Přehled o publikaci